行情

NBRV

NBRV

Nabriva
NASDAQ

实时行情|Nasdaq Last Sale

1.350
-0.080
-5.59%
盘后: 1.360 +0.01 +0.74% 18:54 01/24 EST
开盘
1.430
昨收
1.430
最高
1.440
最低
1.340
成交量
171.66万
成交额
--
52周最高
3.270
52周最低
1.160
市值
1.06亿
市盈率(TTM)
-0.8845
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NBRV 新闻

  • 蛋壳公寓将为武汉医护人员提供专属免费住房
  • 新浪科技.37分钟前
  • 亚澳美欧11国超30例确诊感染 多国计划从武汉撤侨
  • 界面.41分钟前
  • 红杉中国致信成员企业:坚定信心、砥砺前行
  • 新浪财经.2小时前
  • 波音777X完成首飞:明年起开始交付 未来世界最大客机
  • IT之家.3小时前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

NBRV 简况

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use.
展开

Webull提供Nabriva Therapeutics PLC - ADR的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。